Long-term transfer-factor treatment for multiple sclerosis.
In groups of 16 patients with multiple sclerosis, 13 months' double-blind treatment with transfer factor from random normal donors differed from placebo treatment only in producing a temporary restoration of lymphocyte reactivity to measles virus antigen, and did not arrest the degeneration of nerve tissue.
D000328:Adult; D000956:Antigens, Viral; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008459:Measles virus / Q000276:immunology; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000276:immunology / Q000628:therapy*; D013997:Time Factors; D014165:Transfer Factor / Q000008:administration & dosage* / Q000627:therapeutic use
D000956:Antigens, Viral; D014165:Transfer Factor